Guanhao Biotech Co., Ltd
Summary
Revenue :
000,000 M USD
Finance :
000,000 M USD
Earning Cap :
000,000 M USD
Invest :
000,000 M USD
R & D :
0000 People
Growth :
00% AGR
DIGDAL CAP
Overview
| General Introduction | Guanhao Biotechnology Co., Ltd. (stock code: 300238) is a high-tech enterprise based in the regenerative medicine industry, expanding life and health related fields, and grafting global high-end technological resources and achievements. It continues to layout in the fields of biomaterials, cell stem cells, pharmaceuticals, as well as advanced medical technology and product business, forming a "3+1" pattern in its core business, namely the three major business sectors of materials, cells, and pharmaceuticals, and a technology incubation platform. In the field of recycled materials, after more than ten years of development, the company has established an animal derived biomaterial technology platform that is a pharmaceutical technology platform with international competitiveness. With its leading level in the research and development of new biomaterials and their products with induced regeneration functions, the company has undertaken more than 20 national and local scientific and technological research projects, and has become a national level research and development center and industrialization demonstration base in this industry field, The "National Engineering Laboratory for Regenerative Medical Implant Devices" and the "High tech Industrialization Demonstration Project for Regenerative Biofilm" established by the National Development and Reform Commission have successively settled in Guanhao Biotechnology. At present, the company has over a hundred domestic and foreign patents, and its independently developed products that have been launched include biological dural (spinal) patches, B-type dural patches, thoracic and general surgical repair membranes (B/P), sterile biological wound protection membranes, Ario breast patches, and Youde clear acellular corneal grafts; And the artificial lens products represented by Zhuhai Xiangle can be widely used in neurosurgery, general thoracic surgery, ophthalmology, dermatology, orthopedics, plastic surgery, and other fields. In the field of cellular stem cells, the company is currently involved in autologous cartilage tissue cell transplantation technology and immune cell storage technology, and is continuously expanding its research and development in the field of immune cell therapy technology. In the field of stem cells, the company collaborates with the team of Peking University and Professor Deng Hongkui to establish the Beihao Stem Cell and Regenerative Medicine Research Institute, which will build a world-class key technology platform for immune cell commonality, gather a group of globally advanced talents and technologies, and carry out research on stem cells and clinical transformation. In the pharmaceutical industry, Guangdong Zhonghao Pharmaceutical Co., Ltd. and Beijing Wenfeng Tianji Pharmaceutical Technology Co., Ltd., which are controlled by the company, hold intellectual property rights in the Greater China region of Class 1 new drug Benvimod. Benvimod was initially discovered as a non hormonal small molecule compound isolated from a natural microbial metabolite. This drug can be used to treat various autoimmune diseases, such as psoriasis (commonly known as "psoriasis"), and has been listed by the Ministry of Science and Technology as a major scientific and technological achievement in the "12th Five Year Plan" and the "Major New Drug Creation" of the country. In May 2019, the Class 1 innovative drug Benvimod cream was approved for marketing through the priority approval process of the National Drug Administration. In July, it obtained the "Drug GMP Certificate" issued by the Guangdong Provincial Drug Administration. This product is used for local treatment of mild to moderate stable psoriasis vulgaris in adults. In the technology incubation sector, Guanhao Technology Park has created a professional innovation incubation model of "listed companies+incubators+industry funds", committed to creating the most professional industry finance interactive life health innovation and entrepreneurship deep incubation platform in China, and providing overall solutions for entrepreneurial projects and packaged services for industrial transformation. In December 2017, Guanhao Technology Park was recognized as a national level technology enterprise incubator. |
| Headquarter | Guangzhou |
| Establish Date | 10/22/1999 |
| Listed Code | 300238.SZ |
| Listed Date | 7/6/2011 |
| Chairman | Zhang Yongming. |
| CEO | Wang Xinzhi. |
| Website | www.guanhaobio.com |
Buy Premium Now
$15/month billed now
View the full stack of insights immediately
Or 7 Days Free Charge for Trial
See feature available in the Trial and Premium
See our Solution and Servicetrial.solutionservice.trial
See our Uniquness and Value deliveringtrial.solutionservice.trial
